

the relationship of the manufacturer of the drug is usually with the Food and Drug Administration under the Department of Health, Education, and Welfare and/or with the Department of the Treasury.

Do you know currently of any relationship that either you as a psychiatrist or your colleagues who are in the strictly medical profession or the manufacturers of drugs have with the Department of Justice with regard to either the manufacture, licensing, or payment of taxes or the prescription and usage of narcotics or dangerous drugs?

Dr. BARTON. I know of no such relationship.

Mr. BROWN. Is it a fair question to ask that if such relationship existed that you would be aware of it?

Dr. BARTON. Not necessarily.

Mr. BROWN. Well, let's tackle another part of this problem, then. In the utilization of new drugs for patients' treatment and care, have you ever had any relationship with the Justice Department?

Dr. BARTON. I never have.

Mr. BROWN. Have you had this experience of doing any experimental work in the treatment or care of patients with drugs?

Dr. BARTON. Yes, I have.

Mr. BROWN. Doctor, let me ask one final question that is unrelated to psychiatric matters, but related perhaps to the handling of patients who have come under your care or under the care of physicians generally because of their addiction or use of dangerous drugs and narcotics.

Is the emergence of new drugs which have the deprecatory effect on individuals subject to medical analysis, chemical analysis, and scientific analysis?

In other words, when you have a patient who is involved with drugs or narcotics, is it desirable that the effect of the drug or narcotic be examined with reference to what that drug can do to the individual?

Dr. BARTON. Because each drug has its own type of reaction, its own toxic reaction, it is necessary to know as much as one can about the chemical composition and its psycho-pharmacological actions, and if it is a drug that is going to affect the mind or not.

Mr. BROWN. Does this relate perhaps to the kind of treatment which you would prescribe for the individual? That is, in terms of partial withdrawal, or slow withdrawal, psychiatric care, medical treatment, and so forth?

Dr. BARTON. The more specifically you know the action of the drug, the more precise your efforts can be to combat its effects, usually.

Mr. BROWN. So that that there is a relationship not only with the health authorities in our nation with reference to the educational procedure, but also with reference to the medical and psychiatric procedure?

Dr. BARTON. One could say simply, if a drug works at the nerve ending, you could use a drug that blocks the action of the nerve at the nerve endings and thus achieve a neutralizing effect.

Chairman BLATNIK (presiding). Mr. Erlenborn?

Mr. ERLBORN. Thank you, Mr. Chairman.

Dr. Barton, I want to thank you for your testimony. I don't have a long series of questions, really only one, and that is can you tell me